News

November 8, 2019 — Dissection is a frequent and clinically problematic outcome of percutaneous transluminal balloon ...

Home November 08, 2019
Home
News

November 8, 2019 — The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with ...

Home November 08, 2019
Home
Videos | Nuclear Imaging

American Society of Nuclear Cardiology (ASNC) President Rob Beanlands, M.D., shares a couple trends he sees in cardiac nuclear imaging.

Home November 07, 2019
Home
Videos | Artificial Intelligence

Piotr Slomka explains how his team at Cedars-Sinai is working on intelligent patient risk prediction algorithms...

Home November 07, 2019
Home
News | Vascular Access

November 6, 2019 — Saranas Inc. announced completion of the first U.S. commercial case using its Early Bird Bleed ...

Home November 07, 2019
Home
News | Stents Bioresorbable

November 7, 2019 — Although the Abbott Absorb fully bioresorbable drug-eluting stent (DES) was taken off the market due ...

Home November 07, 2019
Home
News | Drug-Eluting Balloons

November 7, 2019 — Real-world, four-year study results of the In.Pact Admiral drug-coated balloon (DCB) demonstrate long ...

Home November 07, 2019
Home
News | Atherectomy Devices

November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs. plain old balloon angioplasty (POBA) ...

Home November 07, 2019
Home
News

November 6, 2019 — Cleveland Clinic announced the Top 10 Medical Innovations for 2020 at a multimedia presentation last ...

Home November 06, 2019
Home
Videos | Nuclear Imaging

Doctor Robert Hendel explains some of the new cardiac radiotracers in the pipeline that were discussed in sessions at the American Society of Nuclear Cardiology (ASNC) 2019 meeting...

Home November 06, 2019
Home
Edwards Sapien 3 TAVI Granted European Approval to Treat Low-risk Patients. TAVR cleared for low risk patients in Europe
Feature

November 6, 2019 — Edwards Lifesciences announced it received European CE mark to expand use of the Edwards Sapien 3 ...

Home November 06, 2019
Home
The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) were evaluated to determine if there is an increased mortality risk due to paclitaxel, but was no difference was seen in the five-year mortality rates compared to control patients. #VIVA19 #VIVA #VIVA2019
Feature | Stents Peripheral | Dave Fornell, Editor

November 6, 2019 – The final, long-term, patient-level data for the Cook Medical Zilver PTX drug-eluting stent (DES) ...

Home November 06, 2019
Home
News | Drug-Eluting Balloons

November 6, 2019 – Positive, two-year data from the first-in-human study of Selution SLR, MedAlliance’s novel sirolimus ...

Home November 06, 2019
Home
News | Peripheral Artery Disease (PAD)

November 6, 2019 – Boston Scientific announced positive data for two of its devices within the peripheral drug-eluting ...

Home November 06, 2019
Home
FDA Warns Troponin Tests Impacted by Biotin Dietary Supplement
Feature | Cardiac Diagnostics | Dave Fornell, Editor

November 5, 2019 — The U.S. Food and Drug Administration (FDA) is updating its November 2017 safety communication to ...

Home November 05, 2019
Home
Subscribe Now